Amgen owes $20.2 million in antibody patent lawsuit, US jury says
A federal jury in Delaware ruled that Amgen subsidiary Teneobio must pay biotech company Harbour Antibodies $20.2 million in damages for infringing a patent related to antibodies used in biologic drugs. The verdict highlights ongoing intellectual property battles in the biologics space, which underpins many cutting-edge drug and longevity therapies. The ruling could have broader implications for how antibody technologies are licensed across the biotech industry.
The Atomic take
The $20.2 million award turns on transgenic-mouse platforms that generate human antibodies, the same upstream tools many longevity-focused biologics depend on to produce their candidates. Because Harbour prevailed on the foundational technology rather than a single drug, expect smaller developers to audit how their antibody-discovery licenses were sourced, and watch whether Teneobio's parent Amgen appeals or pushes to settle. The deeper question is whether this verdict raises the cost of entry for startups building therapies on borrowed antibody-generation methods.
Read the full story at Reuters →Know where humanity is headed.
Five forces. One brief. Free, every Monday morning.
Get The Atomic Five